Asterias Enrolls First Patient in Final Cohort of SCiStar Clinical Trial

http://www.nasdaq.com/press-release/asterias-enrolls-first-patient-in-final-cohort-of-scistar-clinical-trial-20170809-00443

By GlobeNewswire, August 09, 2017, 07:00:00 AM Enrollment for entire SCiStar study expected to be completed by end-2017 FREMONT, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced enrollment and dosing of the first patient in the fifth and final cohort in the company’s ongoing SCiStar Phase 1/2a clinical study of AST-OPC1 in motor complete cervical spinal cord injury (SCI). This cohort will dose between five and eight patients with AIS-B (motor complete, sensory incomplete) cervical spinal cord injuries with 20 million AST-OPC1 cells…